208 related articles for article (PubMed ID: 19522700)
1. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
2. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Huang L; He R; Luo W; Zhu YS; Li J; Tan T; Zhang X; Hu Z; Luo D
Recent Pat Anticancer Drug Discov; 2016; 11(2):184-96. PubMed ID: 26844556
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA
Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790
[TBL] [Abstract][Full Text] [Related]
5. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.
Khayami R; Hashemi SR; Kerachian MA
J Cell Mol Med; 2020 Aug; 24(16):8890-8902. PubMed ID: 32633024
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10.
Zhang W; Wang L; Zhang L; Chen W; Chen X; Xie M; Yan G; Hu X; Xu J; Zhang J
Steroids; 2014 Aug; 86():39-44. PubMed ID: 24793566
[TBL] [Abstract][Full Text] [Related]
7. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
Hojnik M; Frković Grazio S; Verdenik I; Rižner TL
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298614
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
9. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
10. Selective Inhibition of Human AKR1B10 by
Seliger JM; Cicek SS; Witt LT; Martin HJ; Maser E; Hintzpeter J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30469331
[TBL] [Abstract][Full Text] [Related]
11. In Search of Differential Inhibitors of Aldose Reductase.
Balestri F; Moschini R; Mura U; Cappiello M; Del Corso A
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454074
[TBL] [Abstract][Full Text] [Related]
12. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer.
Hojnik M; Šuster NK; Smrkolj Š; Sisinger D; Grazio SF; Verdenik I; Rižner TL
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159076
[TBL] [Abstract][Full Text] [Related]
13. Aldo-keto reductases in the eye.
Huang SP; Palla S; Ruzycki P; Varma RA; Harter T; Reddy GB; Petrash JM
J Ophthalmol; 2010; 2010():521204. PubMed ID: 20628518
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of compound selectivity of aldo-keto reductases using differential scanning fluorimetry.
Kabir A; Endo S; Toyooka N; Fukuoka M; Kuwata K; Kamatari YO
J Biochem; 2017 Feb; 161(2):215-222. PubMed ID: 28003428
[TBL] [Abstract][Full Text] [Related]
16. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
[TBL] [Abstract][Full Text] [Related]
18. Cancer biomarker AKR1B10 and carbonyl metabolism.
Balendiran GK; Martin HJ; El-Hawari Y; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):134-7. PubMed ID: 19028477
[TBL] [Abstract][Full Text] [Related]
19. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
20. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Wang C; Yan R; Luo D; Watabe K; Liao DF; Cao D
J Biol Chem; 2009 Sep; 284(39):26742-8. PubMed ID: 19643728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
